Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)

The report reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Plaque Psoriasis (Psoriasis Vulgaris) therapeutics and enlists all their major and minor projects

The report assesses Plaque Psoriasis (Psoriasis Vulgaris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AbGenomics International, Inc.

Almirall, S.A.

Alteogen Inc.

Amgen Inc.

AstraZeneca Plc

Avexxin AS

BIOCAD

Biocon Limited

Bionovis SA

Boehringer Ingelheim GmbH

Bristol-Myers ...

AbbVie Inc

AbGenomics International, Inc.

Almirall, S.A.

Alteogen Inc.

Amgen Inc.

AstraZeneca Plc

Avexxin AS

BIOCAD

Biocon Limited

Bionovis SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CalciMedica, Inc.

Can-Fite BioPharma Ltd.

Cell Medica Limited

Cellceutix Corporation

Coherus BioSciences, Inc.

Eli Lilly and Company

Epirus Biopharmaceuticals, Inc.

Exicure, Inc.

Forward Pharma A/S

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

Johnson & Johnson

Kadmon Corporation, LLC

Kang Stem Biotech Co., Ltd.

KPI Therapeutics, Inc.

LEO Pharma A/S

Lipidor AB

Lupin Limited

Lycera Corp.

Maruho Co., Ltd.

MetrioPharm AG

Mitsubishi Tanabe Pharma Corporation

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

NeuClone Pty Ltd

Novartis AG

Oncobiologics, Inc.

Pfizer Inc.

Promius Pharma, LLC

Protalix BioTherapeutics, Inc.

Provectus Biopharmaceuticals, Inc.

Sandoz International GmbH

Shanghai Celgen Bio-Pharmaceutical Co., Ltd.

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Company Ltd.

Takeda Pharmaceutical Company Limited

TheraMAB LLC

Therapeutic Proteins International, LLC

UCB S.A.

Valeant Pharmaceuticals International, Inc.

XBiotech Inc

Ziarco Pharma Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Plaque Psoriasis (Psoriasis Vulgaris) Overview 7

Therapeutics Development 8

Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development ...

Table of Contents

Table of Contents 2

Introduction 6

Plaque Psoriasis (Psoriasis Vulgaris) Overview 7

Therapeutics Development 8

Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 9

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 14

Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 18

Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 24

Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 79

Drug Profiles 93

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 261

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 269

Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 271

Appendix 283

List of Tables

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18

Number of Products under Development by Companies, H2 2016 ...

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Development, H2 2016 26

Comparative Analysis by Unknown Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Development by Companies, H2 2016 (Contd..4) 32

Products under Development by Companies, H2 2016 (Contd..5) 33

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016 34

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016 35

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016 36

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016 37

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016 38

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016 39

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016 40

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016 41

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016 42

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016 43

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 44

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016 45

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016 46

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016 47

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016 48

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016 49

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016 50

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016 51

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 52

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016 53

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016 54

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016 55

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016 56

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 57

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016 58

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016 59

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 60

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016 61

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016 62

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016 63

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016 64

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016 65

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016 66

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016 67

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 68

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 69

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016 70

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016 71

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016 72

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016 73

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016 74

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016 75

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 76

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 77

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016 78

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016 79

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 80

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 81

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 82

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016 83

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016 84

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016 85

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 86

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016 87

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016 88

Assessment by Monotherapy Products, H2 2016 89

Assessment by Combination Products, H2 2016 90

Number of Products by Stage and Target, H2 2016 92

Number of Products by Stage and Mechanism of Action, H2 2016 96

Number of Products by Stage and Route of Administration, H2 2016 100

Number of Products by Stage and Molecule Type, H2 2016 102

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016 271

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016 272

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016 273

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016 274

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016 275

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016 276

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016 277

Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016 278

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016 279

Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016 280

List of Figures

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18

Number of Products under Development by Companies, H2 2016 ...

List of Figures

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Products, H2 2016 26

Assessment by Monotherapy Products, H2 2016 89

Assessment by Combination Products, H2 2016 90

Number of Products by Top 10 Targets, H2 2016 91

Number of Products by Stage and Top 10 Targets, H2 2016 91

Number of Products by Top 10 Mechanism of Actions, H2 2016 95

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 95

Number of Products by Routes of Administration, H2 2016 99

Number of Products by Stage and Routes of Administration, H2 2016 99

Number of Products by Molecule Types, H2 2016 101

Number of Products by Stage and Molecule Types, H2 2016 101

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports